Tislelizumab  PD‐1  IgG4  S228P; E233P; F234V; L235A; D265A; L309V; R409K  Stabilize core hinge; mimic IgG2 lower hinge for restricted FcγR specificity; ablate FcγR binding; stabilize CH3 interaction  Oncology  Phase III